Search Result

Isoforms Recommended:	Na_v1.2

Results for "

Nav1.2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Biochemical Assay Reagents (1) Calcium Channel (3) Drug Intermediate (1) GABA Receptor (1) Potassium Channel (2) Small Interfering RNA (siRNA) (3) Sodium Channel (24) TRP Channel (2)
By Research Areas:	Cancer (3) Cardiovascular Disease (1) Neurological Disease (27)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) Antisense Oligonucleotides (2) siRNAs (3)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-16787

ICA-121431 4 Publications Verification	Sodium Channel	Cardiovascular Disease
ICA-121431 is a nanomolar potent and broad-spectrum voltage-gated sodium channel (Na_v) blocker, shows equipotent selectivity for human Na_v1.1 and Na_v1.3 subtypes with IC₅₀ values of 13 nM and 23 nM, respectively. ICA-121431 shows less potent inhibition of Na_v1.2 (IC₅₀=240 nM) and 1,000 fold selectivity against Na_v1.4, Na_v1.6, and the TTX-resistant human Na_v1.5 and Na_v1.8 channels (IC₅₀s >10 μM).

HY-147423

Zandatrigine 1 Publications Verification NBI-921352; XEN901	Sodium Channel	Neurological Disease
Zandatrigine (NBI-921352; XEN901) is a selective, orally active, voltage-gated sodium channel *Na_V1.6*/SCN8A inhibitor that can penetrate the blood-brain barrier. Zandatrigine inhibits sodium influx by non-covalently binding to the VSD4 structure of Na_V1.6, blocking the persistent and resuscitative currents under pathological conditions. Zandatrigine can reduce neuronal hyperexcitability and reduce epileptic seizures. Zandatrigine is 134-756-fold selective for other isoforms such as Na_V1.1 and Na_V1.2, and has minimal effect on Na_V1.1 expressed by inhibitory interneurons. Zandatrigine can be used to study Na_V1.6-mediated neuroexcitability diseases such as SCN8A-related developmental epileptic encephalopathy (SCN8A-DEE) and adult focal epilepsy .

HY-100345

AMTB hydrochloride 2 Publications Verification	TRP Channel	Neurological Disease Cancer
AMTB hydrochloride is a selective TRPM8 channel blocker. AMTB hydrochloride inhibits icilin-induced TRPM8 channel activation with a pIC₅₀ of 6.23. AMTB hydrochloride can be used for the research of the overactive bladder and painful bladder syndrome. AMTB hydrochloride is a non-selective inhibitor of voltage-gated sodium channels (Na_V) .

HY-157786

XPC-5462	Sodium Channel	Neurological Disease
XPC-5462 is a selective *Na_V1.6/1.2* inhibitor, with an IC₅₀ of 0.0103 μM against hNa_V1.6, 0.0137 μM against mNa_V1.6, and 0.0109 μM against *hNa_V1.2*. XPC-5462 significantly reduces epileptiform discharges. XPC-5462 is applicable for epilepsy-related research .

HY-152166

NaV1.2/1.6 channel blocker-1	Sodium Channel	Neurological Disease
NaV1.2/1.6 channel blocker-1 is a potent NaV1.2/1.6 channel blocker, with IC₅₀s of 9.8 and 24.4 μM for rNaV1.6 and *hNaV1.2, respectively. NaV1.2*/1.6 channel blocker-1 can be used for the research of generalized epilepsy .

HY-178963

Nav1.2-IN-2	Sodium Channel Calcium Channel	Neurological Disease
Nav1.2-IN-2 is a *Nav1.2* inhibitor with a human IC₅₀ of 0.18 μM. Nav1.2-IN-2 preferentially binds to the inactivated state of Nav1.2, reduces window current, suppresses neuronal depolarization and action potential generation. Nav1.2-IN-2 suppresses Veratridine (HY-N6691)-induced Ca ²⁺ influx. Nav1.2-IN-2 can be used for the research of epilepsy .

HY-A0079

Tetracaine Amethocaine	Sodium Channel Calcium Channel	Neurological Disease
Tetracaine (Amethocaine) is a sodium channel inhibitor and ryanodine receptor (RyR) inhibitor. Tetracaine blocks sodium conduction across nerve cell membranes, preventing rapid sodium ion influx and depolarization. Tetracaine exhibits biphasic effects on spontaneous sarcoplasmic reticulum Ca ²⁺ release in Ca ²⁺-overloaded ventricular myocytes, and increases sarcoplasmic reticulum Ca ²⁺ load. Tetracaine can be used in research related to eye diseases .

HY-128772

XPC-6444 1 Publications Verification	Sodium Channel	Neurological Disease
XPC-6444 is a highly potent, isoform-selective, and CNS-penetrant *Na_V1.6* inhibitor (IC₅₀=41 nM for hNa_V1.6). XPC-6444 also displays potent block of Na_V1.2 (IC₅₀=125 nM). XPC-6444 shows anticonvulsant activity .

HY-133910

Lu AE98134 1 Publications Verification	Sodium Channel	Neurological Disease
Lu AE98134, an activator of voltage-gated sodium channels, acts as a partly selective Na_v1.1 channels positive modulator. Lu AE98134 also increases the activity of Na_v1.2 and Na_v1.5 channels but not of Na_v1.4, Na_v1.6 and Na_v1.7 channels. Lu AE98134 can be used to analyze pathophysiological functions of the Na_v1.1 channel in various central nervous system diseases, including cognitive restoring in schizophrenia, et al .

HY-20362

4-Azaindole	Biochemical Assay Reagents Drug Intermediate	Neurological Disease Cancer
4-Azaindole is a scaffold. 4-Azaindole can be used in the synthesis of Nav1.2 inhibitors. 4-Azaindole can be used in epilepsy and breast cancer research .

HY-P1073

ProTx-I	Calcium Channel Potassium Channel Sodium Channel TRP Channel	Neurological Disease Cancer
ProTx-I is a toxin derived from Thrixopelma pruriens and a peptide inhibitor targeting TTX-resistant sodium channels. ProTx-I interacts with voltage sensors of multiple domains such as *NaV1.7, reduces neuronal excitability through allosteric modulation of channel gating and alteration of voltage dependence. The IC₅₀* values of ProTx-I against human *NaV1.7, NaV1.2, NaV1.6, and NaV1.5* are 95 nM, 104 nM, 21 nM, and 358 nM, respectively; ProTx-I also potently inhibits Ba ²⁺ currents of hCav3.1, while its inhibitory potency against hCav3.2 is approximately 160-fold lower. ProTx-I is applicable to the research of chronic pain .

HY-126429

Nav1.1 activator 1	Sodium Channel	Neurological Disease
Nav1.1 activator 1 (compound 4), a highly potent *Na_v1.1* activator with BBB penetration, increases decay time constant τ of Na_v1.1 currents at 0.03 μM along with significant selectivity against Na_v1.2, Na_v1.5, and Na_v1.6 .

HY-P1220A

Huwentoxin-IV TFA	Sodium Channel	Neurological Disease
Huwentoxin-IV TFA is a potent and selective sodium channel blocker, inhibits neuronal *Nav1.7, Nav1.2, Nav1.3* and *Nav1.4* with IC₅₀s of 26, 150, 338 and 400 nM, respectively. Huwentoxin-IV TFA preferentially blocks peripheral nerve subtype Nav1.7 by binding neurotoxin receptor site 4. Huwentoxin-IV TFA has analgesic effects on animal models of inflammatory and neuropathic pain .

HY-P1218B

Phrixotoxin 3-NH2 TFA	Sodium Channel	Neurological Disease
Phrixotoxin 3-NH2 TFA is a derivative of Phrixotoxin 3 TFA (HY-P1218A). Phrixotoxin 3 TFA is a potent blocker of voltage-gated sodium channels, with IC₅₀s of 0.6, 42, 72, 288, 610 nM for *NaV1.2, NaV1.3, NaV1.4, NaV1.1* and *NaV1.5*, respectively. Phrixotoxin 3 TFA modulates voltage-gated sodium channels with properties similar to those of typical gating-modifier toxins, both by causing a depolarizing shift in gating kinetics and by blocking the inward component of the sodium current .

HY-P1218

Phrixotoxin 3	Sodium Channel	Neurological Disease
Phrixotoxin 3 is a potent blocker of voltage-gated sodium channels, with IC₅₀s of 0.6, 42, 72, 288, 610 nM for *NaV1.2, NaV1.3, NaV1.4, NaV1.1* and *NaV1.5*, respectively. Phrixotoxin 3 modulates voltage-gated sodium channels with properties similar to those of typical gating-modifier toxins, both by causing a depolarizing shift in gating kinetics and by blocking the inward component of the sodium current .

HY-176065

Nav1.2-IN-1	Sodium Channel	Neurological Disease
Nav1.2-IN-1 (compound 5i), a 3-(1,2,3,6-tetrahydropyridine)-4-azaindole derivative, is a potent and selective *Nav1.2* inhibitor. Nav1.2-IN-1 induces a reduction in the peak amplitude of Nav1.2 currents with an IC₅₀ value of 7.79 μM. Nav1.2-IN-1 exhibits antiepileptic activity. Nav1.2-IN-1 shows high anticonvulsant effect and low neurotoxicity in subcutaneous Pentetrazole (sc-PTZ)-induced epilepsy mode .

HY-P1220

Huwentoxin-IV	Sodium Channel	Neurological Disease
Huwentoxin-IV is a potent and selective sodium channel blocker, inhibits neuronal *Nav1.7, Nav1.2, Nav1.3* and *Nav1.4* with IC₅₀s of 26, 150, 338 and 400 nM, respectively. Huwentoxin-IV preferentially blocks peripheral nerve subtype Nav1.7 by binding neurotoxin receptor site 4. Huwentoxin-IV has analgesic effects on animal models of inflammatory and neuropathic pain .

HY-P5795

GsAF-I	Sodium Channel Potassium Channel	Neurological Disease
GsAF-I is a potent *Na_v* and hERG1 channels blocker with IC₅₀s of 0.36, 0.6, 1.28, 0.33, 1.2, 0.04 and 4.8 μM against Na_v1.1, Na_v1.2, Na_v1.3, Na_v1.4, Na_v1.6, Na_v1.7 and hERG1, respectively .

HY-P5811

Ceratotoxin-1 CcoTx1; β-TRTX-cm1a	Sodium Channel	Neurological Disease
Ceratotoxin-1 (CcoTx1), a peptide toxin, is an voltage-gated sodium channel subtypes inhibitor. Ceratotoxin-1 inhibits *Nav1.1/β1, Nav1.2/β1, Nav1.4/β1, and Nav1.5/β1* with IC₅₀ of 523 nM, 3 nM, 888 nM, and 323 nM, respectively. Ceratotoxin-1 also inhibits *Nav1.8/β1* .

HY-P1218A

Phrixotoxin 3 TFA	Sodium Channel	Neurological Disease
Phrixotoxin 3 TFA is a potent blocker of voltage-gated sodium channels, with IC₅₀s of 0.6, 42, 72, 288, 610 nM for *NaV1.2, NaV1.3, NaV1.4, NaV1.1* and *NaV1.5*, respectively. Phrixotoxin 3 TFA modulates voltage-gated sodium channels with properties similar to those of typical gating-modifier toxins, both by causing a depolarizing shift in gating kinetics and by blocking the inward component of the sodium current .

HY-P5801

Phlo1a μ-TrTx-Phlo1a	Sodium Channel	Neurological Disease
Phlo1a (μ-TrTx-Phlo1a) is a peptide toxin contains 35-amino acid residues. Phlo1b is a selective *Nav1.7* inhibitor. Phlo1a has a weak inhibitory effect on Nav1.2 and Nav1.5 .

HY-P5800

Phlo1b μ-TrTx-Phlo1b	Sodium Channel	Neurological Disease
Phlo1b (μ-TrTx-Phlo1b) is a peptide toxin contains 35-amino acid residues. Phlo1b is a selective *Nav1.7* inhibitor. Phlo1b has a weak inhibitory effect on Nav1.2 and Nav1.5 .

HY-170930

Anticonvulsant agent 9	GABA Receptor Sodium Channel	Neurological Disease
Anticonvulsant agent 9 (compound 4f) is an α1β2γ2 GABAA receptors activator. Anticonvulsant agent 9 activatesα1β2γ2 GABAA receptors with an EC₅₀ of 1.24 μM. Anticonvulsant agent 9 inhibits the inactivation of Nav1.2 channels. Anticonvulsant agent 9 exhibits significant anticonvulsant activities .

HY-P5164

GrTx1	Sodium Channel	Neurological Disease
GrTx1 is a peptide toxin originally isolated from the venom of the spider Grammostola rosea. GrTx1 blocks sodium channel, with IC₅₀s of 0.63 μM, 0.23 μM, 0.77 μM, 1.29 μM, 0.63 μM and 0.37 μM for Nav1.1, Nav1.2, Nav1.3, Nav1.4, Nav1.6 and Nav1.7, repectively . GrTx1 can be used for neurological disease research .

HY-RS12530

Scn2a Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Scn2a Mouse Pre-designed siRNA Set A contains three designed siRNAs for Scn2a gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Scn2a Mouse Pre-designed siRNA Set A Scn2a Mouse Pre-designed siRNA Set A

HY-RS12529

SCN2A Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
SCN2A Human Pre-designed siRNA Set A contains three designed siRNAs for SCN2A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

SCN2A Human Pre-designed siRNA Set A SCN2A Human Pre-designed siRNA Set A

HY-RS12531

Scn2a Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Scn2a Rat Pre-designed siRNA Set A contains three designed siRNAs for Scn2a gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Scn2a Rat Pre-designed siRNA Set A Scn2a Rat Pre-designed siRNA Set A

HY-P5810

Ceratotoxin-2 CcoTx2; β-TRTX-cm1b	Sodium Channel	Neurological Disease
Ceratotoxin-2 (CcoTx2) is a voltage-gated sodium channel blocker with IC₅₀s of 8 nM and 88 nM against Na_v1.2/β₁ and Na_v1.3/β₁, respectively .

HY-183566

MK-5661	Sodium Channel	Neurological Disease
MK-5661 is an orally potent *Na_V1.8* voltage-gated sodium channel inhibitor with an EC₅₀ of 4.3 nM. MK-5661 selectively inhibits peripheral nociceptive signaling mediators. MK-5661 reduces capsaicin-induced spontaneous nociceptive behaviors in humanized rats and attenuates capsaicin-induced skin flushing responses in rhesus monkeys. MK-5661 is applicable for pain-related research .

4-Azaindole	Biochemical Assay Reagents
4-Azaindole is a scaffold. 4-Azaindole can be used in the synthesis of Nav1.2 inhibitors. 4-Azaindole can be used in epilepsy and breast cancer research .

Cat. No.	Product Name	Target	Research Area